The Claim
Tirzepatide does not significantly reduce the risk of stroke compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease, with a hazard ratio of 0.91 (95% CI, 0.76–1.09) over a median follow-up of 47 months.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and existing heart disease, tirzepatide and dulaglutide show similar rates of stroke over nearly four years of follow-up, with no statistically significant difference between the two drugs.
See the scientific wording
Tirzepatide does not significantly reduce the risk of stroke compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease, with a hazard ratio of 0.91 (95% CI, 0.76–1.09) over a median follow-up of 47 months.
Both drugs lower blood sugar and help people lose weight, which reduces strain on blood vessels in the brain. Since both drugs do this similarly, neither ends up being better at preventing strokes.
What the research says
1 studyIn people with diabetes and heart disease, tirzepatide didn’t do a better job than dulaglutide at preventing strokes over four years — the study found no clear difference between the two drugs for stroke risk.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.